comparemela.com

Page 11 - Arnsberg News Today : Breaking News, Live Updates & Top Stories | Vimarsana

West Lothian delegation visit twinned German district

West Lothian delegation visit twinned German district
dailyrecord.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyrecord.co.uk Daily Mail and Mail on Sunday newspapers.

Interprint ponders expansion in Pittsfield, but is mum on specifics

Interprint is asking Pittsfield for an approval to expand, citing storage and production requirements. But it s unclear if it ll go ahead with the expansion.

HeliHub com : Loar Group acquires all shares in SCHROTH

HeliHub com : Loar Group acquires all shares in SCHROTH
helihub.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from helihub.com Daily Mail and Mail on Sunday newspapers.

Press Release: Loar Group acquires SCHROTH Safety Products -

First Patient Enrolled in SELUTION SLR IDE BTK Study

LEIPZIG, Germany, June 8, 2022 /PRNewswire/ The first patient has been enrolled in the FDA IDE BTK (Below-the-Knee) SELUTION4BTK clinical trial involving SELUTION SLR, MedAlliance's novel sirolimus-eluting balloon, just one week after receiving IDE approval. "I am excited to begin an important trial which will establish the evidence that this novel technology benefit patients suffering from CLTI," commented Dr. Michael Lichtenberg, Chief of the Angiology Department at the Klinikum Hochsauerland, Arnsberg, Germany. "So far nothing has worked consistently in this patient population. The early clinical data from SELUTION SLR registries are encouraging and I have seen the performance of this new technology in my routine work. This study is designed to prove that SELUTION SLR is more effective than the current standard of care in this difficult patient population." The start of enrollment in the study follows IDE (Investigational Device Exemption) approval in the U

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.